Literature DB >> 3671250

Comparison of nifedipine, prazosin and hydralazine added to treatment of hypertensive patients uncontrolled by thiazide diuretic plus beta-blocker.

L E Ramsay1, L Parnell, P C Waller.   

Abstract

In 93 patients with hypertension uncontrolled by bendrofluazide 5 mg plus atenolol 100 mg daily, the effects of adding nifedipine (up to 60 mg/day, n = 31), prazosin (up to 20 mg/day, n = 31), or hydralazine (up to 200 mg/day, n = 31) were compared in a 6 month open random parallel group study. The three drugs did not differ significantly as regards antihypertensive effect, withdrawal rate, total number of side effects, or effect on serum biochemical variables. The pattern of side-effects differed. Headache, flushing and oedema were common with nifedipine, tiredness and drowsiness with prazosin, and headache with hydralazine. Nifedipine is an acceptable third-line antihypertensive drug which may have some advantage over hydralazine and prazosin.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3671250      PMCID: PMC2428247          DOI: 10.1136/pgmj.63.736.99

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  7 in total

1.  MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-13

2.  The lupus syndrome induced by hydralazine: a common complication with low dose treatment.

Authors:  H A Cameron; L E Ramsay
Journal:  Br Med J (Clin Res Ed)       Date:  1984-08-18

3.  Side effects of hypotensive agents evaluated by a self-administered questionnaire.

Authors:  C J Bulpitt; C T Dollery
Journal:  Br Med J       Date:  1973-09-01

4.  "Third drug" trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic.

Authors:  D McAreavey; L E Ramsey; L Latham; A D McLaren; A R Lorimer; J L Reid; J I Robertson; M P Robertson; R J Weir
Journal:  Br Med J (Clin Res Ed)       Date:  1984-01-14

5.  Sample size for short-term trials of antihypertensive drugs.

Authors:  S Freestone; J H Silas; L E Ramsay
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

6.  Role of nifedipine in treatment of hypertension.

Authors:  M B Murphy; A J Scriven; C T Dollery
Journal:  Br Med J (Clin Res Ed)       Date:  1983-07-23

7.  Nifedipine in the treatment of hypertension: report of a double-blind controlled trial.

Authors:  S Bayley; R J Dobbs; B F Robinson
Journal:  Br J Clin Pharmacol       Date:  1982-10       Impact factor: 4.335

  7 in total
  3 in total

Review 1.  Resistant hypertension and the Birmingham Hypertension Square.

Authors:  D C Felmeden; G Y Lip
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

2.  Ketanserin, an effective third-line agent in primary hypertension.

Authors:  J J Murphy; P H Whincup; S E Gould; R G Wilcox
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Comparison of ketanserin and slow-release nifedipine added to the treatment of hypertensive patients uncontrolled by a thiazide diuretic plus beta-adrenoceptor blocker.

Authors:  P C Waller; S A Solomon; L E Ramsay
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.